Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-α-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors

Journal of Medicinal Chemistry

Volumn 40, Issue 26, 1997, Pages 4308-4318

  Su, Ting ^a   Naughton, Mary Ann H ^a   Smyth, Mark S ^a   Rose, Jack W ^a   Arfsten, Ann E ^a   McCowan, Jefferson R ^b   Jakubowski, Joseph A ^b   Wyss, Virginia L ^b   Ruterbories, Kenneth J ^b   Sall, Daniel J ^b   Scarborough, Robert M ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[3 (5 AMIDINO 2 BENZOFURANCARBOXAMIDO)PROPIONYL] AMINO] 3 PHENYLPROPIONIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN; PRODRUG; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

ADMINISTRATION, ORAL; ANIMALS; BENZOFURANS; FIBRINOGEN; HUMANS; INDAZOLES; INDOLES; MOLECULAR STRUCTURE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VITRONECTIN; SULFONAMIDES; VITRONECTIN;

EID: 6844236353     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9704863     Document Type: Article

References (38)

1. Bennett, J. S.; Vilaire, G. Exposure of Platelet Fibrinogen Receptor by ADP and Epinephrine, J. Clin. Invest. 1979, 64, 1393-1401.
2. Hawiger, J. Platelet-Vessel Wall Interactions. Platelet Adhesion and Aggregatíon. Atheroscler. Rev. 1990, 21, 165-186.
3. Kieffer, N.; Phillips, D. R. Platelet Membrane Glycoproteins: Functions in Cellular Interactions. Annu. Rev. Cell. Biol. 1990, 6, 329-357.
4. Peerschke, E. I.; Zucker, M. B.; Grant, R. A.; Egan, J. J.; Johnson, M. M. Correlation between Fibrinogen Binding to Human Platelet and Platelet Aggregability. Blood 1980, 55, 841-847.
5. Plow, E. F.; Ginsberg, M. H.; Marguerie, G. A. Expression and Function of Adhesive Protein on the Platelet Surface. In Biochemistry of Platelets; Phillips, D. R., Shuman, M. R., Eds.; Academic Press: New York, 1986; pp 226-251.
6. Scarborough, R. M.; Naughton, M. A.; Teng, W.; Rose, J. W.; Phillips, D. R.; Nannizzi, L.; Arfsten, A.; Campbell, A. M. and Charo, I. F. Design of Potent and Specific Integrin Antagonists. J. Biol. Chem. 1993, 268, 1066-1073.
7. Charo, I. F.; Nannizzi, L.; Phillips, D. R.; Hsu, M. A.; Scarborough, R. M. Inhibition of Fibrinogen Binding to GP IIb-IIIa by a GP IIIa Peptide. J. Biol. Chem. 1991, 266, 1415-1421.
8. Alig, L.; Edenhofer, A.; Hadvary, P.; Hurzeler, M.; Knopp, D.; Muller, M.; Steiner, B.; Trzeciak, A.; and Weller, T. Low Molecular Weight, Non-Peptide Fibrinogen Receptor Antagonists. J. Med. Chem. 1992, 35, 4393-4407.
9. Zablocki, J. A.; Miyano, M.; Garland, R. B.; Pireh, D.; Schretzman, L. A.; Rao, S. N.; Lindmark, R. J.; Panzer-Knodle, S. G.; Nicholson, N. S.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; and Feigen, L. P. Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp-Phe Sequence of Fibrinogen. A Proposal on the Nature of the Binding Interaction Between the Arg-guanidine of RGDX Mimetics and the Platelet GP IIb-IIIa Receptor. J. Med. Chem. 1993, 36, 1811-1819.
10. Zablocki, J. A.; Miyano, M.; Rao, S. N.; Panzer-Knodle, S. G.; Nicholson, N.; Feigen, L. Potent Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp-Phe Sequence of Fibrinogen. A Proposal on the Nature of the Binding Interaction Between the Asp-Carboxylate of RGDX Mimetics and the Platelet GP IIb IIIa Receptor. J. Med. Chem. 1992, 35, 4914-4917.
11. Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T.-C.; Gould, R. J. Non-Peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors. J. Med. Chem. 1992, 35, 4640-4642.
12. Eldred, C. D.; Evans, B.; Hindley, S.; Judkins, B. D.; Kelly, H. A.; Kitchin, P. L.; Porter, B.; ROSS, K. J. S.; Taylor, N. R.; Wheatcroft, J. R. Orally Active Non-Peptide Fibrinogen Receptor (GPIIb/IIIa) Antagonists: Identification of 4-[4-[4-(Aminoiminomethyl)phenyl]-l-piperazinyl]-l-piperidineacetic Acid as a Long-Acting, Broad-Spectrum Antithrombotic Agent. J. Med. Chem. 1994, 37, 3882-3885.
13. Ali, F. E.; Bennett, D. B.; Calvo, R. R.; Elliott, J. D.; Hwang, S.-M.; Ku, T. W.; Lago, M. A.; Nichols, A. J.; Romoff, T. T.; Shah, D. H.; Vasko, J. A.; Wong, A. S.; Yellin, T. O.; Yuan, C.-K.; Samanen, J. M. Conformationally Constrained Peptides and Semipeptides Derived from RGD as Potent Inhibitors of the Platelet Fibrinogen Receptor and Platelet Aggregation. J. Med. Chem. 1994, 37, 769-780.
14. Jackson, S.; DeGrado, W.; Dwivedi, A.; Parthasarathy, A.; Higley, A.; Krywko, J.; Rockwell, A.; Markwalder, J.; Wells, G.; Wexler, R.; Mousa, S.; Harlow, R. Template-Constrained Cyclic Peptides: Design of High-Affinity Ligands for GPIIb/IIIa. J. Am. Chem. Soc. 1994, 116, 3220-3230.
15. McDowell, R. S.; Blackburn, B. K.; Gadek, T. R.; McGee, L. R.; Rawson, T.; Reynolds, M. E.; Robarge, K. D.; Somers, T. C.; Thorsett, E. D.; Tischler, M.; Webb II, R. R. and Venuti, M. C. From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold. J. Am. Chem. Soc. 1994, 116, 5077-5083.
16. For recent reviews, see: (a) Cook, N. S.; Kottirsch, G.; Zerwes, H-G. Drugs Future 1994, 19(2), 135-159. (b) Blackburn, B. K.; Gadek, T. R. Annu. Rep. Med. Chem. 1993, 28, 79-88. (c) Wityak, J.; Sielecki, T. M. Exp. Opin. Ther. Pat. 1996, 6, 1175-1194.
17. For recent reviews, see: (a) Cook, N. S.; Kottirsch, G.; Zerwes, H-G. Drugs Future 1994, 19(2), 135-159. (b) Blackburn, B. K.; Gadek, T. R. Annu. Rep. Med. Chem. 1993, 28, 79-88. (c) Wityak, J.; Sielecki, T. M. Exp. Opin. Ther. Pat. 1996, 6, 1175-1194.
18. For recent reviews, see: (a) Cook, N. S.; Kottirsch, G.; Zerwes, H-G. Drugs Future 1994, 19(2), 135-159. (b) Blackburn, B. K.; Gadek, T. R. Annu. Rep. Med. Chem. 1993, 28, 79-88. (c) Wityak, J.; Sielecki, T. M. Exp. Opin. Ther. Pat. 1996, 6, 1175-1194.
19. (a) McCowan, J.; Arfsten, A.; Berry, D.; Denney, M.; Harms, C.; Jakubowski, J.; Ray, J.; Rose, J.; Sall, D.; Scarborough, R.; Smyth, M. S.; Um, S.; Utterback, B. Platelet Glycoprotein IIb-IIIa Receptor (GP IIb-IIIa) Antagonists Derived from 6,5-Bicyclic Templates, Part I: Generation of a Lead and Template Modifications. ACS 210th National Meeting, Division of Medicinal Chemistry, 1995, Abstract no. 47.
20. (b) Sall, D. J.; Arfsten, A. E.; Berry, D. R.; Denney, M. L.; Harms, C. S.; McCowan, J. R.; Ray, J. K.; Scarborough, R. M.; Um, S. L.; Utterback, B. G.; Jakubowski, J. A. Platelet Glycoprotein IIb-IIIa Receptor (GPIIb-IIIa) Antagonists Derived from Amidinoindoles. Bioorg. Med. Chem. Lett. 1996, 6, 81-86.
21. (c) Sall, D. J.; Arfsten, A. E.; Bastian, J. A.; Denney, M. L.; Harms, C. S.; McCowan, J. R.; Morin, J. M., Jr.; Rose, J. W.; Scarborough, R. M.; Smyth, M. S.; Um, S. L.; Utterback, B. G.; Vaseliff, R. T.; Wyss, V. L.; Jakubowski, J. A. The Use of Conformationally-Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists. J. Med. Chem. 1997, 40 (18), 2843-2857.
22. Wagner, G.; Voigt, B.; Vieweg, H. Synthesis of Na-(Arylsulfonylglycyl)amidinophenylalaninamides as Highly Active Inhibitors of Thrombin. Pharmazie 1984, 39, 226-230.
23. Zablocki, J. A.; Tjoeng, F. S.; Bovy, P. R.; Miyano, M.; Garland, R. B.; Williams, K.; Schretzman, L.; Zupec, M. E.; Rico, J. G.; Lindmark, R. J.; Toth, M. V.; McMackins, D. E.; Adams, S. P.; Panzer-Knodle, S. G.; Nicholson, N. S.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. A Novel Series of Orally Active Antiplatelet Agents. Bioorg. Med. Chem. 1995, 3, 539-551.
24. Metcalf, B. W.; Jung, M. U.S. Pat. 3, 959, 356, 1976.
25. Duggan, M. E.; Ihle, N. C. EP 0 478 362 A2, 1991.
26. Egbertson, M. S.; Chang, C. T.-C.; Duggan, M. E.; Gould, R. J.; Halczenko, W.; Hartman, G. D.; Laswell, W. L.; Lynch, J. J., Jr.; Lynch, R. J.; Manno, P. D.; Naylor, A. M.; Prugh, J. D.; Ramjit, D. R.; Sitko, G. R.; Smith, R. L.; Turchi, L. M.; and Zhang, G. Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp. J. Med. Chem. 1994, 37, 2537-2551.
27. Jetten, M.; Peters, C. A. M.; van Nispen, J. W. F. M.; Ottenheijm, H. C. J. A One-Pot N-Protection of L-Arginine. Tetrahedron Lett. 1991, 32, 6025-6028.
28. Buchi, G.; Lee, G. C. M.; Yang, D.; Tannenbaum, S. R. Direct Acting, Highly Mutagenic, α-Hydroxy N-Nitrosamines from 4-Chloroindoles. J. Am. Chem. Soc. 1986, 108 (14), 4115-4119.
29. (a) Scarborough, R. M.; Rose, J. W.; Naughton, M. A.; Phillips, D. R.; Nannizzi, L.; Campbell, A. M.; Charo, I. F. Characterization of the Integrin Specificities of Disintegrins Isolated from American Pit Viper Venoms. J. Biol. Chem. 1993, 268, 1058-1065.
30. (b) Duggan, M. E.; Naylor-Olsen, A. M.; Perkins, J. J.; Anderson, P. S.; Chang, C. T.-C.; Cook, J. J.; Gould, R. J.; Ihle, N. C.; Hartman, G. D.; Lynch, J. J.; Lynch, R. J.; Manno, P. D.; Schaffer, L. W.; Smith, R. L. Non-Peptide Fibrinogen Receptor Antagonists. 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist. J. Med. Chem. 1995, 38, 3332-3341.
31. Zablocki, J. A.; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzman, L. A.; Rao, S. A.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J.; Toth, M. V.; Zupec, M. E.; McMackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacqmin, P.; Nicholson, N. S.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists. J. Med. Chem. 1995, 38, 2378-2394.
32. Olson, R. E.; Wityak, J. WO 96/37482, 1996.
33. Hutchinson, J. H.; Cook, J. J.; Brashear, K. M.; Breslin, M. J.; Glass, J. D.; Gould, R. J.; Halczenko, W.; Holahan, M. A.; Lynch, R. J.; Sitko, G. R.; Stranieri, M. T.; Hartman, G. D. Non-peptide Glycoprotein IIb/IIIa Antagonists. 11. Design and in vivo Evaluation of 3,4-Dihydro-1(1H)-isoquinolinone-Based Antagonists and Ethyl Ester Prodrugs. J. Med. Chem. 1996, 39, 4583-4591.
34. A full description of the chemical synthesis and biological testing of these and other prodrug compounds to be published separately.
35. (a) Alexander, J.; Cargill, R.; Michelson, S. R.; Schwarm, H. (Acyloxy)alkyl Carbamates as Novel Bioreversible Prodrugs for Amines: Increased Permeation Through Biological Membranes. J. Med. Chem. 1988, 31, 318-322.
36. (b) Folkmann, M.; Lund, F. J. Acyloxymethyl Carbonochloridates. New Intermediates in Prodrug Synthesis. Synthesis 1990, 12, 1159-1166.
37. Scarborough, R. M.; Rose, J. W.; Hsu, M. A.; Phillips, D. A.; Fried, V. A.; Campbell, A. M.; Nannizzi, L.; Charo, I. F. Barbourin. A GPIIb-IIIa Specific Integrin Antagonist from the Venom of Sistrurus m. barbouri. J. Biol. Chem. 1991, 266, 9359-9362.
38. 1 in Promoting Cellular Attachment and Spreading on Fibronectin. J. Cell. Biol. 1990, 111, 2795-2800.